Dr. Reddy's solid dose plant pinched by FDA for missteps

Dr. Reddy's continues to rack up Form 483s as the FDA does a series of inspections on its Indian manufacturing operations. (Dr. Reddy's Laboratories)

The FDA keeps rolling through the Indian manufacturing plants of Dr. Reddy’s Laboratories, and the Form 483s keep falling out.

The FDA this week posted a Form 483 (PDF) for the Dr. Reddy’s solid dose plant in Pradesh that was issued after an inspection in January. There were only four observations, but they covered missteps in some of the basic tenets of quality manufacturing.

The highly redacted Form 483 said that the plant did not do nearly enough to investigate out of spec analysis when stability batches were found to contain impurities. It said the plant had not thoroughly tested the API from the supplier and did not test finished products for the uniformity of impurities in process validation. The inspectors said plant did not extend an investigation into an out of spec tablet batch to see if previously released batches might have the same issue.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

There were also computers and electronic equipment that were not properly password protected. There was no procedure for an operator to take action when an equipment alarm went off during production nor for another operator to report an oil leak he saw in a piece of equipment that was not operating at the time.

RELATED: Dr. Reddy’s oncology drug plant escapes cloud of FDA warning letter

This is more of the same for Dr. Reddy’s, which this month also reported the FDA had issued a Form 483 for its formulations plant in Bachupally that included 11 observations, four of them repeats.

India's second-largest drugmaker did have one important turn of events recently in its struggle to get all of its plants up to FDA expectations. It reported that the FDA had notified it that the steps it has taken to improve operations at its long-troubled oncology formulations plant in Duvvada, India, have finally satisfied the agency. The agency reclassified it as “Voluntary Action Initiated (VAI),” Dr. Reddy’s reported.

The Duvvada facility was one of three plants named in a sweeping FDA warning letter more than three years ago. Follow-up inspections in 2017 and again last October again noted problems.

Suggested Articles

Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.

When it comes to Invokana sales, J&J needs a way to stop the bleeding. And it just took a step closer to a new approval that could do just that.

Novartis last year said its forthcoming SMA gene therapy could be cost effective at up to $5 million. Now, its CEO says the price will be "far lower."